BMS-P5 is a novel, orally active selective inhibitor of peptidylarginine deiminase 4 (PAD4) with an IC50 of 98nM. BMS-P5 blocks multiple myeloma-induced neutrophil extracellular trap (NET) formation. BMS-P5 can be used for research related to multiple myeloma[1-2].
In vivo, starting from day 3 after tumor cell injection, BMS-P5 (50mg/kg; twice daily) was administered by oral gavage to a multiple myeloma mouse model induced by DP42 cells for 20 days. BMS-P5 significantly delayed symptom development and prolonged survival[2].
References:
[1] Cîrciumaru A, Afonso MG, Wähämaa H, et al. Anti-Citrullinated Protein Antibody Reactivity towards Neutrophil-Derived Antigens: Clonal Diversity and Inter-Individual Variation. Biomolecules. 2023 Mar 31;13(4):630.
[2] Li M, Lin C, Deng H, et al. A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Mol Cancer Ther. 2020 Jul;19(7):1530-1538.
















